Addex Therapeutics Files Form 6-K with SEC

Ticker: ADXN · Form: 6-K · Filed: Jun 25, 2025 · CIK: 1574232

Sentiment: neutral

Topics: sec-filing, press-release, disclosure

TL;DR

Addex Therapeutics dropped a 6-K filing on 6/25/25, likely with news.

AI Summary

On June 25, 2025, Addex Therapeutics Ltd. announced the issuance of a press release, incorporated by reference as Exhibit 99.1 to this Form 6-K filing. This press release is expected to contain information relevant to the company's ongoing operations and disclosures.

Why It Matters

This filing indicates that Addex Therapeutics is providing updated information to the SEC, which could include material developments relevant to investors.

Risk Assessment

Risk Level: low — This filing is a routine disclosure and does not appear to contain immediate negative or positive material news.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The primary purpose is to report a press release issued by Addex Therapeutics Ltd. on June 25, 2025, which is incorporated by reference as Exhibit 99.1.

What is the filing date of this Form 6-K?

The filing date is June 25, 2025.

What are the registration numbers mentioned in the filing?

The filing mentions registration numbers 333-255089 for Form F-3 and 333-255124 for Form S-8.

Where is Addex Therapeutics Ltd. located?

Addex Therapeutics Ltd. is located at Chemin des Mines 9, CH-1202 Geneva, Switzerland.

What type of report is this Form 6-K considered?

This Form 6-K is considered a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on June 25, 2025 regarding Addex Therapeutics Ltd. (ADXN).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing